INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Wednesday, April 8, 2026**
Time:	12:00 pm Eastern Time
Location:	Zoom Teleconference
Institution:	Hackensack Meridian Health, Hackensack, NJ
Principal Investigator:	**Andre Goy, MD**
Protocol:	Kite Pharma, Inc., **KT-US-499-0150**
NCT Number:	NCT04989803
Meeting Type:	Continuing Review of Protocol and Site
Title:	A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects with Relapsed and/or Refractory B-cell Lymphoma

1. Call to order:

The Meeting was called to order at 12:20 pm Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution, and the Institution's Biosafety Officer. Also present was IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

The Biosafety Officer confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for KITE-363 and KITE-753, since they consist of genetically modified primary human cells. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of KITE-363 and KITE-753 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. The Committee noted that a staff member is due for IATA Shipping Training recertification in May 2026.
2. The Committee noted that the Biological Safety Cabinet (BSC) Certifications indicate that some of the certifying company's equipment used to certify the BSC were due for recalibration in 2026.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Biosafety Officer.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 12:24 pm Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:
Agenda
Protocol, Amendment 6.0, dated 02-13-2026
KITE-753, Investigator's Brochure, Edition 3.0, dated 09-12-2025, Corrected
KITE-363, Investigator's Brochure, Version 8.0, dated 10-15-2025
KITE-753, Investigational Product Manual, Version 6.0, dated 10-09-2025
KITE-363, Investigational Product Manual, Version 7.0, dated 11-24-2025
Research Modification Evaluation, Protocol, Amendment 5.0
Research Modification Evaluation, Protocol, Amendment 6.0
Research Modification Evaluation, KITE-753, Investigator's Brochure, Edition 3.0, Corrected
Research Modification Evaluation, KITE-753, Investigator's Brochure, Edition 3.0
Research Modification Evaluation, KITE-363, Investigator's Brochure, Version 7.0
Research Modification Evaluation, KITE-363, Investigator's Brochure, Version 8.0
Research Modification Evaluation, KITE-363, Investigational Product Manual, Version 6.0
Research Modification Evaluation, KITE-363, Investigational Product Manual, Version 7.0
Research Modification Evaluation, KITE-753, Investigational Product Manual, Version 5.0
Research Modification Evaluation, KITE-753, Investigational Product Manual, Version 6.0
Biological Risk Assessment and Summary, updated 03-10-2026
Site Maps, Genetically Modified Human Cells, updated 11-19-2025
Site Inspection Checklist, Genetically Modified Human Cells, expires 08-19-2026, updated 03-26-2026
Biohazard Sign, Goy, dated 04-15-2025
Biological Safety Cabinet Certifications, CTMF, expire 05-31-2026
Biosafety Guidelines for Genetically Modified Human Cells, dated 12-11-2025
Biosafety Guidelines, Addendum for Autologous Cells, dated 03-26-2026
Training, Shipping Certifications, expire 05-2026, 10-2026, 11-2026, 12-2026, 2027
CRRF, dated 01-20-2026
Prior Meeting Minutes, Continuing, dated 04-29-2025